The relationship between thrombin activatable fibrinolysis inhibitor and coronary heart disease
10.19485/j.cnki.issn2096-5087.2020.12.005
- Author:
ZHAO Meng Nan
;
TIAN Pei Ru
;
QIU Li
;
LI Yu Ning
;
WANG Xiao Nan
;
YI Bo Yu
;
SHI Jing Pu
- Publication Type:Journal Article
- Keywords:
thrombin activatable fibrinolysis inhibitor；coronary heart disease；case-control study
- From:
Journal of Preventive Medicine
2020;32(12):1208-1212
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the relationship between thrombin activatable fibrinolysis inhibitor ( TAFI ) and coronary heart disease ( CHD ), and to provide evidence for the prevention of CHD.
Methods:The patients with CHD in Fushun Central Hospital in Liaoning Province were selected as the case group, the patients without CHD in the same hospital and period were selected as the control group. The demographic information and clinical examination results ( serum TAFI, lipid, glucose, etc. ) were collected to analyze the association between TAFI and CHD by logistic regression models.The multivariate logistic regression analysis was used to explore the relationship between TAFI and CHD.
Results:There were 222 cases, including 100 cases of stable angina, 44 cases of unstable angina and 78 cases of acute myocardial infarction, and 222 controls. The median ages of cases and controls were 62 and 57 years old. The results of multivariate logistic regression analysis showed that serum TAFI>22.88 μg/mL ( P75 of controls ) was associated with the risk of CHD ( OR=1.619, 95%CI: 1.011-2.593 ), unstable angina ( OR=2.917, 95%CI: 1.433-5.939 ) and acute myocardial infarction ( OR=2.626, 95%CI: 1.007-6.847 ).
Conclusion:The high level of TAFI is related to CHD, unstable angina and acute myocardial infarction.
- Full text:凝血酶激活的纤溶抑制物与冠心病关系研究.pdf
